SCHEMBL4088056

SCHEMBL4088056

CON(C)C(=O)c1cccc(Br)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.43
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
CLK1 P49759 3/20 0.40
TRPM8 Q7Z2W7 2/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
HTR7 P34969 2/20 0.37
CYP1A2 P05177 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 1/20 0.37
RECQL P46063 1/20 0.37
DYRK1A Q13627 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
MLYCD O95822 1/20 0.36
KDM4E B2RXH2 2/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
ACMSD Q8TDX5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8374791 0.88 KDM4E (0.45) ALDH1A1CLK1TRPM8MEN1KMT2A
SCHEMBL19151565 0.84 CYP1A2 (0.44) GRM5ALDH1A1HPGDCLK1TRPM8
SCHEMBL31546875 0.83 CTSA (0.40) CLK1TRPM8MEN1KMT2ATDP1
SCHEMBL31546869 0.83 CTSA (0.40) CLK1TRPM8MEN1KMT2ATDP1
SCHEMBL30911644 0.82 GRM5 (0.47) GRM5ALDH1A1HPGDCLK1MEN1
SCHEMBL188335 0.82 GRM5 (0.47) GRM5ALDH1A1HPGDCLK1MEN1
SCHEMBL3739445 0.81 P2RX7 (0.49) GRM5ALDH1A1CLK1TRPM8MEN1
SCHEMBL306066 0.80 ALDH1A1 (0.41) ALDH1A1HPGDCLK1TRPM8MEN1
SCHEMBL307224 0.80 GRM4 (0.46) ALDH1A1CLK1TRPM8MEN1KMT2A
SCHEMBL14880117 0.80 TRPM8 (0.39) ALDH1A1CLK1TRPM8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
US-12331046-B2 CTPS1 inhibitors and uses thereof NIMBUS CLOTHO, INC. (US) 2025-06-17 US disclosed
EP-4232425-A1 CTPS1 INHIBITORS AND USES THEREOF Nimbus Clotho, Inc. (US) 2023-08-30 EP disclosed
CN-116601131-A CTPS1 inhibitor and application thereof 林伯士克洛索有限公司 2023-08-15 CN disclosed
US-20230077316-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-09 US disclosed
EP-3625225-B1 LDHA ACTIVITY INHIBITORS ARCTIC PHARMA AS (NO) 2022-06-29 EP disclosed
EP-3625225-B1 LDHA ACTIVITY INHIBITORS ARCTIC PHARMA AS (NO) 2022-06-29 EP disclosed
WO-2022087634-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2022-04-28 WO disclosed
WO-2022087634-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2022-04-28 WO disclosed
US-11142520-B2 LDHA activity inhibitors ARCTIC PHARMA AS (NO) 2021-10-12 US disclosed
WO-2015140133-A1 PIPERIDINE-DIONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-09-24 WO disclosed
US-7595325-B2 Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment PFIZER INC. (US) 2009-09-29 US disclosed
US-7338960-B2 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-7338960-B2 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-7338960-B2 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
EP-1513526-B1 PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS SMITHKLINE BEECHAM CORP (US) 2007-11-07 EP disclosed
EP-1773836-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT Pfizer Products Inc. (US) 2007-04-18 EP disclosed
US-20060089394-A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators SMITHKLINE BEECHAM CORPORATION 2006-04-27 US disclosed
US-20060035912-A1 Pyrrolopyrimidine derivatives useful in cancer treatment PFIZER INC 2006-02-16 US disclosed
WO-2005116035-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT PFIZER PRODUCTS INC. (US) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF SLC10A1, NR3C2, CYP2C8 GRM5 497/4885ALDH1A1 230/4885HPGD 932/4885
US-20060035912-A1 Pyrrolopyrimidine derivatives useful in cancer treatment TP53, DPYD, CCNT1 GRM5 3870/4885ALDH1A1 125/4885HPGD 629/4885
US-20060089394-A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators LIPA, PNLIP, CEL GRM5 3072/4885ALDH1A1 903/4885HPGD 227/4885
US-20230077316-A1 CTPS1 INHIBITORS AND USES THEREOF CTPS1, CTPS2, ECHS1 GRM5 4566/4885ALDH1A1 1472/4885HPGD 1139/4885
US-11142520-B2 LDHA activity inhibitors LDHA, LDHB, PDHA1 GRM5 3834/4885ALDH1A1 9/4885HPGD 259/4885
US-12331046-B2 CTPS1 inhibitors and uses thereof CTPS1, CTPS2, ECHS1 GRM5 4566/4885ALDH1A1 1472/4885HPGD 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.